AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...
FierceBiotech8h
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...
cnbctv185h
AstraZeneca Pharma gets nod to launch cancer drug durvalumab in India
The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...
Here’s Why AstraZeneca PLC (AZN) Surged in Q2
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...
ndtvprofit4h
AstraZeneca Pharma Gets Approval To Import And Distribute Durvalumab For Cancer Treatment
This approval allows Durvalumab to be used together with chemotherapy before surgery, and then as a single treatment ...
AstraZeneca breast cancer drug trial fails to extend lives of patients
It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...
Business Insider15h
AstraZeneca’s Market Position and Drug Pipeline Sustain Buy Rating Despite TB01 Trial Results
James Gordon has given his Buy rating due to a combination of factors surrounding AstraZeneca’s position in the market and the assessment of their drug development pipeline. Firstly, despite the final ...
AstraZeneca: TROPION-Breast01 Phase III Trial Fails To Achieve Statistical Significance
Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...